Home
Account
Research Tools
Educate
Contribute
News
Sectors
Premium
About Us
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Chart School
Tutorials
Learning Center
Glossary
Submit Article
Join Blog Network
Rate Broker
Rate Software
Earnings
Dividend
Management Changes
M&A
Analyst
FDA
IPO
About Us
Contact Us
Advertise With Us
Editorial Staff
Terms and Conditions
Privacy Policy
iStock Rating
D
Details...
Enter Symbol
Allos Therapeutics, Inc. (NASDAQ: ALTH)
Sector: Medical
Current Price :
$1.84
52 Week Low
$1.25
52 Week High
$1.94
Company
Overview
Research Notes
Company Profile
Competitors
Community
Stock Sentiment
Whisper Estimates
Enter Estimates
Message Board
Analysis
Blog Articles
Press Releases
Charts
Technical Charts
Analyst
Analyst Ratings
Analyst Estimates
Sales Estimates
Ratios
Financial Ratios
Technicals
Press Releases
Spectrum Pharmaceuticals and Allos Therapeutics Announce Expiration of Offering Period and Final Completion of Tender Offer for Shares of Allos Therapeutics
Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics
Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics
Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics
Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics
Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics
Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics
Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics
Spectrum Pharmaceuticals and Allos Therapeutics Announce Extension of Previously Announced Tender Offer For Shares of Allos Therapeutics
Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Allos Therapeutics, Inc.
Allos Therapeutics Announces Outcome of Request for Re-examination of CHMP Opinion for FOLOTYN? in Europe
Spectrum Pharmaceuticals Commences Tender Offer for All Outstanding Shares of Allos Therapeutics
Allos Therapeutics, Inc. (ALTH) Shareholder Alert: Bernstein Liebhard LLP Announces Investigation of Acquisition By Spectrum Pharmaceuticals
Block & Leviton LLP Investigates Allos Therapeutics, Inc. for Possible Breaches of Fiduciary Duties for Its Proposed Merger with Spectrum Pharmaceuticals
Spectrum Pharmaceuticals to Acquire Allos Therapeutics: Acquisition Expected to Be Accretive on a Cash Basis in Q4 of 2012
Allos Therapeutics Reports Fourth Quarter and Full Year 2011 Financial Results
Allos Therapeutics Requests Re-Examination of CHMP Opinion on FOLOTYN? in PTCL at the European Medicines Agency
Allos Therapeutics Invites Investors to Listen to Webcast of Presentation at J.P. Morgan Healthcare Conference
Allos Therapeutics Reports Third Quarter 2011 Financial Results
Allos Therapeutics Announces Settlement with Putative Class Action Plaintiffs Regarding Merger with AMAG Pharmaceuticals
Strong Pipelines From Allos Therapeutics and Dynavax Tech Poised to Pay Off
Allos Therapeutics Continues to Work Toward Completion of Merger with AMAG Pharmaceuticals
Robbins Geller Rudman & Dowd LLP Files Class Action Suit against Allos Therapeutics, Inc.
Allos Therapeutics Initiates Phase 3 Registration Trial of FOLOTYN? in Newly Diagnosed Patients with Peripheral T-Cell Lymphoma Following Treatment with a CHOP-based Regimen
Allos Therapeutics Reports Second Quarter 2011 Financial Results
MSMB Capital Proposes Acquisition of Amag Pharmaceuticals for $18 Per Share
Allos Therapeutics to Report Second Quarter 2011 Results on August 4, 2011
The Law Firm of Weiss & Lurie Announces Investigation of Allos Therapeutics, Inc.
Law Offices of Howard G. Smith Announces Investigation of Allos Therapeutics, Inc.
Bull & Lifshitz, LLP Announces Investigation of Allos Therapeutics, Inc.
Goldfarb Branham Law Firm LLP Investigates Allos Therapeutics Inc Company
MURRAY FRANK LLP Investigates Allos Therapeutics, Inc.
The Briscoe Law Firm and Powers Taylor, LLP Announce Investigation of Allos Therapeutics, Inc.
Robbins Umeda LLP Announces an Investigation of Allos Therapeutics, Inc.
Law Office of Brodsky & Smith, LLC Announces Investigation of Allos Therapeutics, Inc.
The Law Firm of Levi & Korsinsky, LLP Announces Investigation of Allos Therapeutics, Inc.
Harwood Feffer LLP Announces Investigation of Allos Therapeutics, Inc.
Kendall Law Group Investigates Allos Therapeutics, Inc.
Faruqi & Faruqi, LLP Announces Investigation of Allos Therapeutics, Inc.
AMAG Pharmaceuticals and Allos Therapeutics Agree to Merge to Strengthen Commercial Portfolio and Achieve Cost Synergies
Data Shows Activity of FOLOTYN(R) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma Following Treatment with CHOP
Research Report on Allos Therapeutics, Inc. and Spectrum Pharmaceuticals, Inc. -- BioPharm Looks Forward for Growth
Data Suggests Treatment with FOLOTYN(R) Reverses Trend of Progressive Resistance Observed in Patients with Drug-Resistant Relapsed or Refractory Peripheral T-Cell Lymphoma
COMPLETE Registry Provides First Glance into Treatment Patterns for Patients with Peripheral T-Cell Lymphoma
FOLOTYN(R) Data to be Presented at the Congress of the European Hematology Association and the International Conference on Malignant Lymphoma
Allos Therapeutics and Mundipharma Announce Strategic Collaboration for FOLOTYN
Allos Therapeutics Reports First Quarter 2011 Financial Results
Allos Therapeutics to Present at Upcoming Investor Conferences in May
Allos Therapeutics to Report First Quarter 2011 Results on May 10, 2011
Oncology Drug Makers Positioned for Long Term Growth
Allos Therapeutics to Present at Upcoming Investor Conferences
Speculative Biotech Firms Remain Popular Takeover Targets
Allos Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of FOLOTYN in Patients with Previously Undiagnosed Peripheral T-cell Lymphoma
Allos Therapeutics Reports Fourth Quarter and Full Year 2010 Financial Results
Allos Therapeutics to Report Fourth Quarter and Full Year 2010 Results on March 3, 2011
Journal of Clinical Oncology Publishes Results from Pivotal Phase 2 PROPEL Study of FOLOTYN(R) in Relapsed or Refractory Peripheral T-Cell Lymphoma
Allos Therapeutics Reports 2010 Financial Highlights and 2011 Key Business Priorities
Allos Therapeutics Announces Topline Results from Phase 2b Study of FOLOTYN in Patients with Advanced Non-Small Cell Lung Cancer
Fundamental data is provided by
Zacks Investment Research
, and Commentary, news and Press Releases provided by YellowBrix and
Quotemedia
. Advertisement partners
Investing Channel
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.
{1}
##LOC[OK]##
{1}
##LOC[OK]##
##LOC[Cancel]##
{1}
##LOC[OK]##
##LOC[Cancel]##